Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Icon ( (ICLR) ) is now available.
On September 24, 2025, ICON plc announced it will release its third-quarter 2025 financial results on October 22, 2025, and will host a conference call and webcast on October 23, 2025, to discuss its financial performance. This announcement is significant as it provides stakeholders with insights into the company’s financial health and operational performance, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (ICLR) stock is a Buy with a $189.00 price target. To see the full list of analyst forecasts on Icon stock, see the ICLR Stock Forecast page.
Spark’s Take on ICLR Stock
According to Spark, TipRanks’ AI Analyst, ICLR is a Outperform.
Icon’s overall stock score reflects solid financial performance and a balanced earnings call sentiment. The company’s strong profitability and stable balance sheet are significant strengths. Technical indicators suggest a neutral market position, while valuation metrics indicate reasonable pricing. Despite challenges from elevated cancellations and revenue declines, strategic growth initiatives and cost management provide a positive outlook.
To see Spark’s full report on ICLR stock, click here.
More about Icon
ICON plc is a world-leading clinical research organization headquartered in Dublin, Ireland. It provides outsourced services to pharmaceutical, biotechnology, medical device, and government and public health organizations, focusing on advancing clinical research from molecule to medicine. As of June 30, 2025, ICON employed approximately 39,900 employees across 95 locations in 55 countries.
Average Trading Volume: 1,269,750
Technical Sentiment Signal: Sell
Current Market Cap: $13.03B
Learn more about ICLR stock on TipRanks’ Stock Analysis page.